Business Standard

Sanofi may underperform in near term; pricing control among key risks

The decline was largely on account of divestment of its nutraceutical business and a few key brands.

Sanofi
Premium

The brokerage believes that the divestment of the two brands could keep a check on the company’s revenues in the September quarter.

Ram Prasad Sahu
The stock of pharma multinational Sanofi India has been hitting fresh 52-week lows over the past fortnight, shedding about 10 per cent from its July highs. The weak operating performance in June quarter of the 2022-23 financial year (Q1FY23) has led to the recent decline and the stock may underperform in the near term.

Revenues in the June quarter were down 11 per cent year-on-year (YoY) and 1 per cent sequentially, to Rs 700 crore, and missed the Street expectations. The decline was largely on account of divestment of its nutraceutical business and a few key brands. The company had

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 31 2022 | 8:10 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com